Yingchun Zhang

Yingchun Zhang

Auto-generated profile, based on publicly available information

Yingchun Zhang

Sun Yat-sen University Cancer Center 2 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Guangzhou, P. R. China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
HXHuaiyuan Xu
Huaiyuan Xu
JHJinxin Hu
Jinxin Hu
YZYun Zhang
Yun Zhang
AZAihua Zhuang
Aihua Zhuang
YZYingchun Zhang
Yingchun Zhang
JWJin Wang
Jin Wang
Purpose: To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in the treatment of desmoid tumors (DT). Patients and Methods: In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles. Crossover from placebo to PLD was permitted upon disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints were objective response and safety. Results: From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with an HR of 0.05 (95% confidence interval, 0.01–0.17; P < 0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo. PFS benefit favored PLD across most prespecified subgroups. The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and in one (4.3%) in the placebo group (P = 0.002). Common grade 3 or higher adverse events with PLD included neutrophil count decreased (10.6%), mucositis oral (6.4%), and white cell decreased (4.3%). Significant between-group differences in certain patient-reported toxicities were observed (P < 0.05). Conclusions: PLD significantly prolonged PFS and induced durable responses compared with placebo, with a favorable safety profile, for patients with progressive or symptomatic DTs. See related commentary by Dossa et al., p. 2127

1 June 2026
Verified
Other
Open access
HXHuaiyuan Xu
Huaiyuan Xu
JHJinxin Hu
Jinxin Hu
YZYun Zhang
Yun Zhang
AZAihua Zhuang
Aihua Zhuang
YZYingchun Zhang
Yingchun Zhang
JWJin Wang
Jin Wang
Table S1. Representativeness of study participants


1 June 2026
Verified
Other
Open access
HXHuaiyuan Xu
Huaiyuan Xu
JHJinxin Hu
Jinxin Hu
YZYun Zhang
Yun Zhang
AZAihua Zhuang
Aihua Zhuang
YZYingchun Zhang
Yingchun Zhang
JWJin Wang
Jin Wang
Purpose:To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in the treatment of desmoid tumors (DT).Patients and Methods:In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles. Crossover from placebo to PLD was permitted upon disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints were objective response and safety.Results:From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with an HR of 0.05 (95% confidence interval, 0.01–0.17; P < 0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo. PFS benefit favored PLD across most prespecified subgroups. The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and in one (4.3%) in the placebo group (P = 0.002). Common grade 3 or higher adverse events with PLD included neutrophil count decreased (10.6%), mucositis oral (6.4%), and white cell decreased (4.3%). Significant between-group differences in certain patient-reported toxicities were observed (P < 0.05).Conclusions:PLD significantly prolonged PFS and induced durable responses compared with placebo, with a favorable safety profile, for patients with progressive or symptomatic DTs.See related commentary by Dossa et al., p. 2127

1 June 2026
Verified
Other
Open access
HXHuaiyuan Xu
Huaiyuan Xu
JHJinxin Hu
Jinxin Hu
YZYun Zhang
Yun Zhang
AZAihua Zhuang
Aihua Zhuang
YZYingchun Zhang
Yingchun Zhang
JWJin Wang
Jin Wang
Figure S3. Distribution of PRO-CTCAE scores at successive time points during active therapy and maximum score post-baseline without and with baseline adjustment